Immunotherapeutic Approaches in the Treatment of Infectious Diseases: Recent Breakthroughs

Harada Kevin^*
*Correspondence: Harada Kevin, Department of Infectious Diseases, University of Bristol, Beacon House, Queens Rd, Bristol BS8 1QU, UK, Email:

Keywords

Immunotherapy • Infectious diseases • Immune system

Introduction

Infectious diseases remain a major global health challenge, causing significant morbidity and mortality worldwide. Traditional treatment options, such as antibiotics and antiviral drugs, have played a crucial role in managing infectious diseases. However, the emergence of drug resistance and the limitations of conventional therapies have spurred the development of innovative immunotherapeutic approaches. In recent years, significant breakthroughs have been made in harnessing the power of the immune system to combat infectious diseases. This article explores some of the recent advancements in immunotherapeutic approaches and their potential impact on the treatment of infectious diseases.

Passive immunization involves the administration of pre-formed antibodies to provide immediate immunity against pathogens. This approach is particularly useful in emergency situations or for individuals with compromised immune systems. Convalescent plasma, derived from individuals who have recovered from an infection, contains a high concentration of antibodies specific to the pathogen. It has been successfully used in the treatment of diseases such as Ebola, influenza, and COVID-19. Monoclonal antibodies, which are laboratoryproduced antibodies, are another form of passive immunization that can be designed to target specific pathogens [1]. Active immunization involves stimulating the immune system to generate a protective immune response against a particular pathogen. Vaccines are the most common form of active immunization. Traditional vaccines have been highly effective in preventing infectious diseases by priming the immune system to recognize and mount a response against specific pathogens. Ongoing research aims to develop new vaccines or improve existing ones, including the development of novel vaccine platforms and the use of adjuvants to enhance immune responses.

Description

While vaccines are primarily used for prevention, therapeutic vaccines are designed to treat individuals who are already infected. These vaccines aim to stimulate an immune response that specifically targets and eliminates the pathogen. Therapeutic vaccines have shown promise in the treatment of chronic viral infections, such as human papillomavirus (HPV), hepatitis B, and HIV. They can potentially reduce viral loads, slow disease progression, and improve immune control over the infection. T-cell therapy involves the manipulation and reinfusion of a patient's own T cells to enhance the immune response against pathogens [2]. One notable example is the use of chimeric antigen receptor (CAR) T-cell therapy, which has demonstrated remarkable success in treating certain cancers. CAR T-cell therapy is also being explored for infectious diseases, particularly viral infections. By genetically modifying T cells to express receptors specific to viral antigens, CAR T cells can recognize and eliminate infected cells, offering a targeted and potent immunotherapeutic approach.

Cytokines are small proteins that play a vital role in regulating immune responses.

Cytokine therapy involves the administration of specific cytokines to modulate the immune system and enhance its ability to combat infections. For instance, interferon therapy has been used for the treatment of hepatitis B and C infections, stimulating antiviral responses and reducing viral replication. Interleukin-2 (IL-2) therapy has been explored in HIV infection to boost immune cell production and enhance immune control over the virus. Immune checkpoint inhibitors have revolutionized cancer treatment by unleashing the immune system's ability to recognize and attack cancer cells [3]. These inhibitors block proteins that regulate immune checkpoints, allowing immune cells to mount a more robust response against cancer. In the context of infectious diseases, immune checkpoint inhibitors are being investigated as a potential strategy to overcome immune exhaustion and enhance immune responses. This approach may be particularly useful in chronic infections, where the immune response is often dysregulated and ineffective.

Monoclonal antibodies (mAbs) are laboratory-produced antibodies designed to target specific pathogens or components of the immune system. Recent breakthroughs have led to the development of highly effective mAbs against various infectious agents. For example, mAbs targeting the Ebola virus have shown promising results in clinical trials, reducing mortality rates and improving patient outcomes. Similarly, mAbs have been developed for respiratory syncytial virus (RSV), Clostridium difficile infection, and other bacterial and viral pathogens [4]. These mAbs can provide immediate immunity and complement the body's natural defense mechanisms against pathogens. Adoptive cell therapies involve the transfer of immune cells to enhance the immune response against infectious agents. One notable breakthrough in this field is the use of chimeric antigen receptor (CAR) T-cell therapy. CAR-T cells are engineered immune cells that express receptors specific to a target pathogen. They have shown significant success in treating certain types of cancer, and their potential in infectious disease treatment is being explored. CAR-T cell therapy has shown promise against viral infections, such as HIV and hepatitis B, by targeting viral antigens and effectively eliminating infected cells.

Vaccines have long been used as a preventive measure against infectious diseases. However, recent advancements have focused on developing therapeutic vaccines that can treat ongoing infections. Therapeutic vaccines aim to boost the immune response against a specific pathogen in individuals who are already infected. For example, therapeutic vaccines for chronic viral infections, such as HIV and hepatitis C, have shown encouraging results in clinical trials. These vaccines stimulate the immune system to target and control the infection, potentially leading to sustained viral suppression. Immune checkpoint inhibitors are a class of immunotherapeutic drugs that enhance the body's immune response by blocking proteins that regulate immune checkpoints. While initially developed for cancer treatment, they have also shown promise in infectious diseases. By inhibiting immune checkpoints, these drugs can overcome the immunosuppressive effects of certain pathogens and enhance the immune response [5]. For instance, immune checkpoint inhibitors have demonstrated efficacy in treating tuberculosis and chronic hepatitis B infections by boosting immune clearance of the pathogens.

Cytokines are small proteins that play a crucial role in regulating immune responses. Recent breakthroughs in cytokine-based therapies have shown potential for treating infectious diseases. For example, interleukin-2 (IL-2) therapy has been explored in HIV infection to increase the production of immune cells that target the virus. Additionally, interferon therapies have been used in the treatment of hepatitis B and C, enhancing antiviral immune responses and reducing viral replication. The human microbiome, consisting of trillions of microorganisms inhabiting our bodies, has a significant impact on our immune system and overall health. Recent research has focused on developing microbiome-based therapies to combat infectious diseases.

Conclusion

Immunotherapeutic approaches hold significant promise in the treatment of infectious diseases. Passive immunization with antibodies, active immunization through vaccines, therapeutic vaccines, T-cell therapy, cytokine therapy, and immune checkpoint inhibitors are all innovative strategies that aim to harness the immune system's capabilities to combat pathogens. Continued research and development in these areas, along with clinical trials to assess safety and efficacy, will be crucial in further advancing immunotherapy as a viable option for the treatment of infectious diseases. As our understanding of the immune system improves, immunotherapeutic approaches have the potential to transform the landscape of infectious disease management, providing new avenues for more effective and targeted treatments.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Ramamurthy, Dharanidharan, Trishana Nundalall, Sanele Cingo and Neelakshi Mungra, et al. "Recent advances in immunotherapies against infectious diseases." Immunother adv 1 (2021): ltaa007.

Google Scholar, Crossref, Indexed at

2. Look, Michael, Arunima Bandyopadhyay, Jeremy S. Blum and Tarek M. Fahmy. "Application of nanotechnologies for improved immune response against infectious diseases in the developing world."            Adv Drug Deliv Rev 62 (2010): 378-393.

Google Scholar, Crossref, Indexed at

3. Bookstaver, Michelle L., Shannon J. Tsai, Jonathan S. Bromberg and Christopher M. Jewell. "Improving vaccine and immunotherapy design using biomaterials." Trends Immunol 39 (2018): 135-150.

Google Scholar, Crossref, Indexed at

4. Waldmann, Thomas A. "Immunotherapy: Past, present and future." Nat Med 9 (2003): 269-277.

Google Scholar, Crossref, Indexed at

5. Xu, Zhijie, Shuangshuang Zeng, Zhicheng Gong and Yuanliang Yan. "Exosome-based immunotherapy: A promising approach for cancer treatment." Mol Cancer 19 (2020): 1-16.

Google Scholar, Crossref, Indexed at